Jack D Goldstein

US Patent:

20010006772, Jul 5, 2001

Filed:

Dec 12, 2000

Appl. No.:

09/735400

Inventors:

Jack Goldstein - New York NY, US
Leslie Lenny - Brooklyn NY, US
Rosa Hurst - Staten Island NY, US

International Classification:

A01N001/02

US Classification:

435/002000, 435/440000

Abstract:

The present invention relates to an improved method for enzymatically removing blood type-specific antigens from erythrocytes, comprising titrating the pH of the erythrocytes first to a pH suitable for enzyme activity and then, once the desired extent of antigen removal has been achieved, to a pH appropriate for storage and/or transfusion. The buffers used for titration have pH values significantly above or below the target pHs for erythrocyte conversion or storage/transfusion. The invention is based, at least in part, on the discovery that the structural integrity of the erythrocytes is not substantially disrupted by titration. The present invention further relates to methods wherein the addition of polyethylene glycol improves the efficiency of enzymatic removal of erythrocyte antigens.

US Patent:

54787386, Dec 26, 1995

Filed:

Feb 8, 1994

Appl. No.:

8/194116

Inventors:

Jack Goldstein - New York NY
Rosa S. Hurst - Staten Island NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

C12N 926

US Classification:

435201

Abstract:

This invention relates to an improved method of purifying the enzyme. alpha. -N-acetylgalactosaminidase from avian liver, as well as to the purified enzyme. The enzyme is capable of removing A antigens from the surface of cells in blood products. The method of purifying the enzyme is simple and time efficient, and lends itself to large scale production.

US Patent:

43306195, May 18, 1982

Filed:

Aug 14, 1980

Appl. No.:

6/177972

Inventors:

Jack Goldstein - New York NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

A01N 102
A61K 3514

US Classification:

435 2

Abstract:

A composition comprising type O erythrocyte free of P. sub. 1 antigenicity; a method of converting erythrocytes of the B antigen type to erythrocytes of the H-antigen type which comprises: A. equilibrating said erythrocytes to a pH of 5. 7-5. 8; B. thereafter contacting the so-equilibrated erythrocytes with an enzyme for a period sufficient to convert the B antigen in said erythrocytes to the H-antigen; C. thereafter removing said enzyme from said erythrocytes and D. re-equilibrating said erythrocytes to a pH of 7. 2-7. 4. The specification discloses conversion of the B antigens in human and animal blood to the H antigen (O cells).

US Patent:

44277776, Jan 24, 1984

Filed:

Aug 13, 1981

Appl. No.:

6/292558

Inventors:

Jack Goldstein - New York NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

C12N 0500
A61K 3514
A01N 100

US Classification:

435240

Abstract:

Transfusable type O erythrocytes free of P1 antigenicity which are produced by an alpha-galactosidase conversion of type B antigen to type H antigen. The resulting erythrocytes retain a high level of ATP and 2,3 DPG.

US Patent:

59255412, Jul 20, 1999

Filed:

Sep 11, 1996

Appl. No.:

8/712072

Inventors:

Jack Goldstein - New York NY
Alex Zhu - New York NY
Lin Leng - New York NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

C12P 2106

US Classification:

435 691

Abstract:

The present invention relates to purified and isolated nucleic acid encoding the endo-. beta. -galactosidase from Flavobacterium keratolyticus (referred to as "ENDO-A"), and to purified ENDO-A protein. The endo-. beta. -galactosidase of the invention may be used in a process which enzymatically de-antigenizes human erythrocytes bearing A. sub. 1 antigen. The resulting erythrocytes may be transfused into individuals who would be otherwise unable to tolerate a transfusion of type A. sub. 1 blood.

US Patent:

46096272, Sep 2, 1986

Filed:

Aug 1, 1983

Appl. No.:

6/518980

Inventors:

Jack Goldstein - New York NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

C07K 300
A01N 102
C12N 924
C12N 940

US Classification:

435269

Abstract:

Type O erythrocytes are produced from certain subtypes of A erythrocytes or type AB erythrocytes by contacting the same following equilibration of a pH of 5. 6-5. 8 with an. alpha. -N-acetylgalactosaminidase, preferably obtained from an avian liver, for periods sufficient to convert the A antigen in the erythrocyte to the H antigen. Following removal of the enzyme, the erythrocyte is re-equilibrated to a pH of 7. 2-7. 4. As a result, there is obtained O type erythrocytes characterized by a 60 to 90 percent ATP level based on the level of ATP in naturally occurring O or AB erythrocytes. Beginning with certain A cells one obtains synthetic O erythrocytes characterized by a terminal. alpha. -fucose moiety, O antigenicity, and the absence of A antigenicity. Beginning with A. sub.

US Patent:

62286315, May 8, 2001

Filed:

Apr 30, 1998

Appl. No.:

9/070356

Inventors:

Alex Zhu - New York NY
Jack Goldstein - New York NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

C12N 940
C12N 924
C12N 1556
C12N 510
C12N 1563

US Classification:

435208

Abstract:

This invention relates to a recombinant enzyme for use in the removal of A antigens from the surface of cells in blood products. Specifically, this invention is directed to a recombinant. alpha. -N-acetylgalactosaminidase enzyme from chicken liver, methods of cloning and expressing said recombinant. alpha. -N-acetylgalactosaminidase enzyme and a method of removing A antigens from the surface of cells in blood products using said recombinant. alpha. -N-acetylgalactosaminidase enzyme.